Long-Acting Injectable Cabotegravir for HIV Prevention
Publication Date: July 28, 2022
Last Updated: August 2, 2022
New Recommendation
Long-acting injectable cabotegravir may be offered as an additional prevention choice for people at substantial risk of HIV infection, as part of combination prevention approaches. (C, M)
620
Key messages on HIV testing for CAB-LA
- It is important for programmes to select a testing strategy and algorithm that promotes access to CAB-LA among those who would benefit most.
- Programmes can employ the current national HIV testing strategy and algorithm, using a combination of RDTs and enzyme immunoassays according to WHO recommendations.
- Some countries and programmes may include NAT where feasible, in addition to the national algorithm, particularly at initiation, prior to the presence of ARVs. Where NAT is implemented, it is important to have the necessary assays, resources, regulatory approvals and a clear testing strategy for resolving discrepant results and establishing HIV infection before initiating life-long ART.
- Countries need to consider the feasibility of using NAT before CAB-LA initiation, and while taking CAB-LA. While NAT before CAB-LA initiation, and while taking CAB-LA, might prevent a small number of cases of drug resistance, countries need to consider the feasibility of NAT. There are also uncertainties as to what impact these mutations will have on subsequent ART.
- Ongoing monitoring of implementation is needed to further optimize HIV testing approaches for CAB-LA.
Overview
Title
Long-Acting Injectable Cabotegravir for HIV Prevention
Authoring Organization
World Health Organization